Heron Therapeutics | HRTX - Current Assets


Heron Therapeutics reported $229.4M in Current Assets for its fiscal quarter ending in September of 2025.





Current Assets Change Date
ALKERMES USD 1.93B 187.5M Dec/2025
Alnylam Pharmaceuticals USD 4.05B 97.85M Dec/2025
Amarin USD 628.33M 21.52M Sep/2025
ANI Pharmaceuticals USD 753.12M 54.72M Dec/2025
Anika Therapeutics USD 101.59M 2.27M Sep/2025
Arrowhead Research USD 1.17B 223.75M Dec/2025
Eisai JPY 840.88B 50.18B Dec/2025
Emergent BioSolutions USD 679.5M 41.3M Dec/2023
Esperion Therapeutics USD 360.46M 17.87M Sep/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Heron Therapeutics USD 229.4M 18.48M Sep/2025
Insmed USD 1.79B 137.6M Dec/2025
Ligand Pharmaceuticals USD 832.27M 78.35M Dec/2025
Merck USD 47.56B 10.49B Sep/2025
Nektar Therapeutics USD 281.36M 94.79M Sep/2025
Neurocrine Biosciences USD 2.52B 364.3M Dec/2025
Omeros USD 69.65M 26.53M Jun/2025
Pacira USD 547.97M 14.78M Dec/2025
Regeneron Pharmaceuticals USD 18.02B 41.2M Dec/2025
Roche Holding CHF 38.73B 3.03B Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Surmodics USD 81.3M 948K Sep/2024
Ultragenyx Pharmaceutical USD 643.21M 76.58M Sep/2025
Veracyte USD 488.38M 39.15M Dec/2025
Vertex Pharmaceuticals USD 11.2B 631.4M Dec/2025